Indolent Lymphoma Treatment Market, Global Outlook and Forecast 2022-2028

March 2022 | 66 pages | ID: I974D5B9A999EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Indolent Lymphoma Treatment in Global, including the following market information:

Global Indolent Lymphoma Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Indolent Lymphoma Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

BI-836826 Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Indolent Lymphoma Treatment include Altor BioScience Corporation, Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Indolent Lymphoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Indolent Lymphoma Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Indolent Lymphoma Treatment Market Segment Percentages, by Type, 2021 (%)

• BI-836826
• ALT-803
• BMS-986016
• CC-122
• Others

Global Indolent Lymphoma Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Indolent Lymphoma Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Indolent Lymphoma Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Indolent Lymphoma Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Indolent Lymphoma Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Indolent Lymphoma Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Altor BioScience Corporation
• Amgen Inc.
• Astellas Pharma Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Incyte Corporation
• Infinity Pharmaceuticals, Inc.
• Juno Therapeutics Inc.
• MedImmune, LLC

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Indolent Lymphoma Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Indolent Lymphoma Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL INDOLENT LYMPHOMA TREATMENT OVERALL MARKET SIZE

2.1 Global Indolent Lymphoma Treatment Market Size: 2021 VS 2028
2.2 Global Indolent Lymphoma Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Indolent Lymphoma Treatment Players in Global Market
3.2 Top Global Indolent Lymphoma Treatment Companies Ranked by Revenue
3.3 Global Indolent Lymphoma Treatment Revenue by Companies
3.4 Top 3 and Top 5 Indolent Lymphoma Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Indolent Lymphoma Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Indolent Lymphoma Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Indolent Lymphoma Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Indolent Lymphoma Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Indolent Lymphoma Treatment Market Size Markets, 2021 & 2028
  4.1.2 BI-836826
  4.1.3 ALT-803
  4.1.4 BMS-986016
  4.1.5 CC-122
  4.1.6 Others
4.2 By Type - Global Indolent Lymphoma Treatment Revenue & Forecasts
  4.2.1 By Type - Global Indolent Lymphoma Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Indolent Lymphoma Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Indolent Lymphoma Treatment Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Indolent Lymphoma Treatment Revenue & Forecasts
  5.2.1 By Application - Global Indolent Lymphoma Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Indolent Lymphoma Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Indolent Lymphoma Treatment Market Size, 2021 & 2028
6.2 By Region - Global Indolent Lymphoma Treatment Revenue & Forecasts
  6.2.1 By Region - Global Indolent Lymphoma Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Indolent Lymphoma Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Indolent Lymphoma Treatment Revenue, 2017-2028
  6.3.2 US Indolent Lymphoma Treatment Market Size, 2017-2028
  6.3.3 Canada Indolent Lymphoma Treatment Market Size, 2017-2028
  6.3.4 Mexico Indolent Lymphoma Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Indolent Lymphoma Treatment Revenue, 2017-2028
  6.4.2 Germany Indolent Lymphoma Treatment Market Size, 2017-2028
  6.4.3 France Indolent Lymphoma Treatment Market Size, 2017-2028
  6.4.4 U.K. Indolent Lymphoma Treatment Market Size, 2017-2028
  6.4.5 Italy Indolent Lymphoma Treatment Market Size, 2017-2028
  6.4.6 Russia Indolent Lymphoma Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Indolent Lymphoma Treatment Market Size, 2017-2028
  6.4.8 Benelux Indolent Lymphoma Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Indolent Lymphoma Treatment Revenue, 2017-2028
  6.5.2 China Indolent Lymphoma Treatment Market Size, 2017-2028
  6.5.3 Japan Indolent Lymphoma Treatment Market Size, 2017-2028
  6.5.4 South Korea Indolent Lymphoma Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Indolent Lymphoma Treatment Market Size, 2017-2028
  6.5.6 India Indolent Lymphoma Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Indolent Lymphoma Treatment Revenue, 2017-2028
  6.6.2 Brazil Indolent Lymphoma Treatment Market Size, 2017-2028
  6.6.3 Argentina Indolent Lymphoma Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue, 2017-2028
  6.7.2 Turkey Indolent Lymphoma Treatment Market Size, 2017-2028
  6.7.3 Israel Indolent Lymphoma Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Indolent Lymphoma Treatment Market Size, 2017-2028
  6.7.5 UAE Indolent Lymphoma Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Altor BioScience Corporation
  7.1.1 Altor BioScience Corporation Corporate Summary
  7.1.2 Altor BioScience Corporation Business Overview
  7.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Major Product Offerings
  7.1.4 Altor BioScience Corporation Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.1.5 Altor BioScience Corporation Key News
7.2 Amgen Inc.
  7.2.1 Amgen Inc. Corporate Summary
  7.2.2 Amgen Inc. Business Overview
  7.2.3 Amgen Inc. Indolent Lymphoma Treatment Major Product Offerings
  7.2.4 Amgen Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.2.5 Amgen Inc. Key News
7.3 Astellas Pharma Inc.
  7.3.1 Astellas Pharma Inc. Corporate Summary
  7.3.2 Astellas Pharma Inc. Business Overview
  7.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Major Product Offerings
  7.3.4 Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.3.5 Astellas Pharma Inc. Key News
7.4 Bayer AG
  7.4.1 Bayer AG Corporate Summary
  7.4.2 Bayer AG Business Overview
  7.4.3 Bayer AG Indolent Lymphoma Treatment Major Product Offerings
  7.4.4 Bayer AG Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.4.5 Bayer AG Key News
7.5 Boehringer Ingelheim GmbH
  7.5.1 Boehringer Ingelheim GmbH Corporate Summary
  7.5.2 Boehringer Ingelheim GmbH Business Overview
  7.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Major Product Offerings
  7.5.4 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.5.5 Boehringer Ingelheim GmbH Key News
7.6 Bristol-Myers Squibb Company
  7.6.1 Bristol-Myers Squibb Company Corporate Summary
  7.6.2 Bristol-Myers Squibb Company Business Overview
  7.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Major Product Offerings
  7.6.4 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.6.5 Bristol-Myers Squibb Company Key News
7.7 Celgene Corporation
  7.7.1 Celgene Corporation Corporate Summary
  7.7.2 Celgene Corporation Business Overview
  7.7.3 Celgene Corporation Indolent Lymphoma Treatment Major Product Offerings
  7.7.4 Celgene Corporation Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.7.5 Celgene Corporation Key News
7.8 Eli Lilly and Company
  7.8.1 Eli Lilly and Company Corporate Summary
  7.8.2 Eli Lilly and Company Business Overview
  7.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Major Product Offerings
  7.8.4 Eli Lilly and Company Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.8.5 Eli Lilly and Company Key News
7.9 F. Hoffmann-La Roche Ltd.
  7.9.1 F. Hoffmann-La Roche Ltd. Corporate Summary
  7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
  7.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Major Product Offerings
  7.9.4 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.9.5 F. Hoffmann-La Roche Ltd. Key News
7.10 Gilead Sciences, Inc.
  7.10.1 Gilead Sciences, Inc. Corporate Summary
  7.10.2 Gilead Sciences, Inc. Business Overview
  7.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Major Product Offerings
  7.10.4 Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.10.5 Gilead Sciences, Inc. Key News
7.11 Incyte Corporation
  7.11.1 Incyte Corporation Corporate Summary
  7.11.2 Incyte Corporation Business Overview
  7.11.3 Incyte Corporation Indolent Lymphoma Treatment Major Product Offerings
  7.11.4 Incyte Corporation Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.11.5 Incyte Corporation Key News
7.12 Infinity Pharmaceuticals, Inc.
  7.12.1 Infinity Pharmaceuticals, Inc. Corporate Summary
  7.12.2 Infinity Pharmaceuticals, Inc. Business Overview
  7.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Major Product Offerings
  7.12.4 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.12.5 Infinity Pharmaceuticals, Inc. Key News
7.13 Juno Therapeutics Inc.
  7.13.1 Juno Therapeutics Inc. Corporate Summary
  7.13.2 Juno Therapeutics Inc. Business Overview
  7.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Major Product Offerings
  7.13.4 Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.13.5 Juno Therapeutics Inc. Key News
7.14 MedImmune, LLC
  7.14.1 MedImmune, LLC Corporate Summary
  7.14.2 MedImmune, LLC Business Overview
  7.14.3 MedImmune, LLC Indolent Lymphoma Treatment Major Product Offerings
  7.14.4 MedImmune, LLC Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
  7.14.5 MedImmune, LLC Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Indolent Lymphoma Treatment Market Opportunities & Trends in Global Market
Table 2. Indolent Lymphoma Treatment Market Drivers in Global Market
Table 3. Indolent Lymphoma Treatment Market Restraints in Global Market
Table 4. Key Players of Indolent Lymphoma Treatment in Global Market
Table 5. Top Indolent Lymphoma Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Indolent Lymphoma Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Indolent Lymphoma Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Indolent Lymphoma Treatment Product Type
Table 9. List of Global Tier 1 Indolent Lymphoma Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Indolent Lymphoma Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Indolent Lymphoma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Indolent Lymphoma Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Indolent Lymphoma Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Indolent Lymphoma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Indolent Lymphoma Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Indolent Lymphoma Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Indolent Lymphoma Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Indolent Lymphoma Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Indolent Lymphoma Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Indolent Lymphoma Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Indolent Lymphoma Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Indolent Lymphoma Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Indolent Lymphoma Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Altor BioScience Corporation Corporate Summary
Table 31. Altor BioScience Corporation Indolent Lymphoma Treatment Product Offerings
Table 32. Altor BioScience Corporation Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Amgen Inc. Corporate Summary
Table 34. Amgen Inc. Indolent Lymphoma Treatment Product Offerings
Table 35. Amgen Inc. Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Astellas Pharma Inc. Corporate Summary
Table 37. Astellas Pharma Inc. Indolent Lymphoma Treatment Product Offerings
Table 38. Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Bayer AG Corporate Summary
Table 40. Bayer AG Indolent Lymphoma Treatment Product Offerings
Table 41. Bayer AG Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Boehringer Ingelheim GmbH Corporate Summary
Table 43. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product Offerings
Table 44. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Bristol-Myers Squibb Company Corporate Summary
Table 46. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product Offerings
Table 47. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Celgene Corporation Corporate Summary
Table 49. Celgene Corporation Indolent Lymphoma Treatment Product Offerings
Table 50. Celgene Corporation Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly and Company Corporate Summary
Table 52. Eli Lilly and Company Indolent Lymphoma Treatment Product Offerings
Table 53. Eli Lilly and Company Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 54. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 55. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product Offerings
Table 56. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Gilead Sciences, Inc. Corporate Summary
Table 58. Gilead Sciences, Inc. Indolent Lymphoma Treatment Product Offerings
Table 59. Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Incyte Corporation Corporate Summary
Table 61. Incyte Corporation Indolent Lymphoma Treatment Product Offerings
Table 62. Incyte Corporation Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Infinity Pharmaceuticals, Inc. Corporate Summary
Table 64. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product Offerings
Table 65. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Juno Therapeutics Inc. Corporate Summary
Table 67. Juno Therapeutics Inc. Indolent Lymphoma Treatment Product Offerings
Table 68. Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)
Table 69. MedImmune, LLC Corporate Summary
Table 70. MedImmune, LLC Indolent Lymphoma Treatment Product Offerings
Table 71. MedImmune, LLC Indolent Lymphoma Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Indolent Lymphoma Treatment Segment by Type in 2021
Figure 2. Indolent Lymphoma Treatment Segment by Application in 2021
Figure 3. Global Indolent Lymphoma Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Indolent Lymphoma Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Indolent Lymphoma Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2021
Figure 8. By Type - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 12. US Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 24. China Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Indolent Lymphoma Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Altor BioScience Corporation Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Amgen Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bayer AG Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Celgene Corporation Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly and Company Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Incyte Corporation Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. MedImmune, LLC Indolent Lymphoma Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)